3 results on '"De bonnecaze, G."'
Search Results
2. Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey.
- Author
-
Favier V, Daveau C, Carsuzaa F, Fieux M, Vandersteen C, Castillo L, Papon JF, de Gabory L, Saroul N, Verillaud B, Rumeau C, Jankowski R, Michel J, de Bonnecaze G, Lecanu JB, Coste A, Béquignon E, Malard O, and Mortuaire G
- Subjects
- Humans, Chronic Disease, Prospective Studies, France, Observational Studies as Topic, Omalizumab therapeutic use, Multicenter Studies as Topic, Rhinosinusitis, Nasal Polyps drug therapy, Nasal Polyps complications, Sinusitis drug therapy, Rhinitis drug therapy, Rhinitis complications, Biological Products therapeutic use
- Abstract
Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a frequent condition affecting approximately 2% of the population. Medical treatment consists long-term use of intranasal corticosteroids and short-term use of oral corticosteroids, in adjunct with saline solution rinses. Surgical management is proposed in patients who failed after medical treatment. In France, two biologics are reimbursed in case of severe uncontrolled CRSwNP despite medical treatment and endoscopic sinus surgery. Waiting for head-to-head biologics comparison, studies should report the efficacy and safety of biologics in large real-life cohorts. This study protocol describes the aims and methods of a prospective, observational, national, multicentric cohort of patients with CRSwNP treated with biologics., Methods and Analysis: The BIOlogics in severe nasal POlyposis SurvEy is a French multicentre prospective observational cohort study. The main aim is to assess the efficacy and tolerance of biologics in patients with CRSwNP, with or without association with other type 2 diseases, and to determine the strategies in case of uncontrolled disease under biologics. Patients over 18 years old requiring biologics for CRSwNP in accordance with its marketing approval in France (ie, severe nasal polyposis, with lack of control under nasal corticosteroid, systemic corticosteroids and surgery) are invited to participate. Collected data include topical history of surgical procedures and biologics, medication and use of systemic corticosteroids, visual analogical scales for specific symptoms, Sino-Nasal Outcome Test-22 questionnaire, nasal polyp score, asthma control test, Lund-Mackay score on CT scan and IgE concentration and eosinophilic count on blood sample., Trial Registration: NCT05228041/DRI_2021/0030., Competing Interests: Competing interests: All authors report personal fees as expert consultant for Sanofi and GlaxoSmithKline., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
3. The Prognostic Value of Olfactory Dysfunction in Patients with COVID-19: The COVIDORA Study.
- Author
-
Hamel AL, Delbos L, Natella PA, Radulesco T, Alexandru M, Bartaire E, Bartier S, Benoite G, Bequignon E, Castillo L, Canouï-Poitrine F, Carsuzaa F, Corré A, Coste A, Couloigner V, Daveau C, De Boissieu P, De Bonnecaze G, De Gabory L, Debry C, Deraedt S, Dufour X, El Bakkouri W, Gilain L, Hans S, Hautefort C, Hermann R, Jankowski R, La Croix C, Lecanu JB, Malard O, Michel J, Nguyen Y, Nevoux J, Papon JF, Patron V, Prigent M, Pruliere-Escabasse V, Renaud M, Rumeau C, Salmon D, Saroul N, Serrano E, Nhung Tran Khai C, Tringali S, Truy E, Vandersteen C, Verillaud B, Veil R, and Fieux M
- Abstract
Background: Among all studies describing COVID-19 clinical features during the first wave of the pandemic, only a few retrospective studies have assessed the correlation between olfac-tory dysfunction (OD) and the evolution of disease severity. The main aim was to assess whether OD is a predictive factor of COVID-19 severity based on the patient's medical management (outpa-tient care, standard hospital admission, and ICU admission)., Methods: A national, prospective, mul-ticenter cohort study was conducted in 20 public hospitals and a public center for COVID-19 screen-ing. During the first wave of the pandemic, from 6 April to 11 May 2020, all patients tested positive for COVID-19 confirmed by RT-PCR underwent two follow-up ENT consultations within 10 days of symptom onset. The main outcome measures were the evolution of medical management (out-patient care, standard hospital admission, and ICU admission) at diagnosis and along the clinical course of COVID-19 disease., Results: Among 481 patients included, the prevalence of OD was 60.7%, and it affected mostly female patients (74.3%) under 65 years old (92.5%), with fewer comor-bidities than patients with normal olfactory function. Here, 99.3% (290/292) of patients with OD presented with non-severe COVID-19 disease. Patients reporting OD were significantly less hospi-talized than the ones managed as outpatients, in either a standard medical unit or an ICU. Conclu-sions: As regards the clinical course of COVID-19 disease, OD could predict a decreased risk of hospitalization during the first wave of the pandemic.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.